Degron Therapeutics, a clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines announced that it has entered into a joint development collaboration agreement with Merck & Co., Inc., Rahway, N.J., USA, to jointly advance the clinical development of molecular glue candidates in oncology.
